L
Liyan Jiang
Researcher at Shanghai Chest Hospital
Publications - 5
Citations - 129
Liyan Jiang is an academic researcher from Shanghai Chest Hospital. The author has contributed to research in topics: Adenocarcinoma & Carboplatin. The author has an hindex of 2, co-authored 5 publications receiving 77 citations.
Papers
More filters
Journal ArticleDOI
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Baohui Han,Qing-yu Xiu,Huimin Wang,Jie Shen,Aiqin Gu,Yi Luo,Chunxue Bai,Shu-liang Guo,Wenchao Liu,Zhixiang Zhuang,Yang Zhang,Yi-zhuo Zhao,Yi-zhuo Zhao,Liyan Jiang,Jianying Zhou,Xian-qiao Jin +15 more
TL;DR: In previously untreated, advanced NSCLC patients, treatment with TC plus endostar seemed to improve ORR, however, the differences in PFS or OS between the two groups were not statistically significant.
Journal ArticleDOI
Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.
James Chih-Hsin Yang,Mengzhao Wang,Paul Mitchell,Jian Fang,Weiqi Nian,Chao-Hua Chiu,Jianying Zhou,Yanqiu Zhao,Wu Chou Su,D. Ross Camidge,Tsung-Ying Yang,Viola W. Zhu,Michael Millward,Yun Fan,Wen Tsung Huang,Ying Cheng,Liyan Jiang,Li Zheng,Xiuhui Ye,Pasi A. Jänne +19 more
TL;DR: DZD9008 is a rationally designed selective, irreversible EGFR exon20ins inhibitor being developed for the treatment of mutant NSCLC.
Journal ArticleDOI
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Xinghao Ai,Yueyin Pan,Jianhua Shi,Nong Yang,Chunling Liu,Jianying Zhou,Xiaodong Zhang,Xiaorong Dong,Jianxing He,Xiao-Ling Li,Gongyan Chen,Xingya Li,Helong Zhang,Wangjun Liao,Yiping Zhang,Zhiyong Ma,Liyan Jiang,Jiuwei Cui,Chunhong Hu,Wei Wang,Cheng Huang,Jun Zhao,Cuimin Ding,X. Hu,Kai Wang,Beili Gao,Yong Song,Xiaoqing Liu,Jianping Xiong,Anwen Liu,Junling Li,Zhe Liu,Yinyin Li,Mengzhao Wang,Biao Zhang,Dan Zhang,Shun Lu +36 more
TL;DR: ZL-2306-005 as discussed by the authors is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with extensive-stage SCLC (ES-SCLC).
Journal ArticleDOI
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Tao Jiang,Liyan Jiang,Xiaorong Dong,Kangsheng Gu,Yueyin Pan,Qin Shi,Guojun Zhang,Huijuan Wang,Xiaochun Zhang,Nong Yang,Yuping Li,Jianping Xiong,Tienan Yi,Min Peng,Yong Song,Yun Fan,Jiuwei Cui,Gongyan Chen,Wei Tan,Aimin Zang,Qisen Guo,Guangqiang Zhao,Ziping Wang,Jianxing He,Wenxiu Yao,Xiaohong Wu,Kai Chen,Xiaohua Hu,Chunhong Hu,Lu Yue,Da Jiang,Guangfa Wang,Junfeng Liu,Guohua Yu,Junling Li,Henghui Zhang,Lihong Wu,Lu Fang,Dandan Liang,Yi Zhao,Weihong Zhao,Wenmin Xie,Shengxiang Ren,Caicun Zhou +43 more
TL;DR: Findings indicated that the RS, a circulating cfDNA sequencing-based stratification index, could help to guide first-line chemotherapy in advanced LUSC and the change of VAF is valuable to monitor the treatment response.